<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "journalpublishing3.dtd">
<article xml:lang="en" article-type="research-article" xmlns:xlink="http://www.w3.org/1999/xlink">
<?release-delay 0|0?>
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">ETM</journal-id>
<journal-title-group>
<journal-title>Experimental and Therapeutic Medicine</journal-title>
</journal-title-group>
<issn pub-type="ppub">1792-0981</issn>
<issn pub-type="epub">1792-1015</issn>
<publisher>
<publisher-name>D.A. Spandidos</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="publisher-id">ETM-0-0-8950</article-id>
<article-id pub-id-type="doi">10.3892/etm.2020.8950</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Expression levels of CXCR4 and CXCL12 in patients with rheumatoid arthritis and its correlation with disease activity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Peng</surname><given-names>Liping</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
<xref rid="fn1-etm-0-0-8950" ref-type="author-notes">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhu</surname><given-names>Ning</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
<xref rid="fn1-etm-0-0-8950" ref-type="author-notes">&#x002A;</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mao</surname><given-names>Jing</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Huang</surname><given-names>Li</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Yang</surname><given-names>Yameng</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Zhou</surname><given-names>Zhengju</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Li</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Wu</surname><given-names>Bin</given-names></name>
<xref rid="af1-etm-0-0-8950" ref-type="aff"/>
<xref rid="c1-etm-0-0-8950" ref-type="corresp"/>
</contrib>
</contrib-group>
<aff id="af1-etm-0-0-8950">Department of Rheumatology and Immunology, First People&#x0027;s Hospital of Jingzhou, The First Affiliated Hospital of Yangtze University, Jingzhou, Hubei 434000, P.R. China</aff>
<author-notes>
<corresp id="c1-etm-0-0-8950"><italic>Correspondence to:</italic> Dr Bin Wu, Department of Rheumatology and Immunology, First People&#x0027;s Hospital of Jingzhou, The First Affiliated Hospital of Yangtze University, 8 Hangkong Road, Jingzhou, Hubei 434000, P.R. China <email>binglaw@163.com</email></corresp>
<fn id="fn1-etm-0-0-8950"><p><sup>&#x002A;</sup>Contributed equally</p></fn>
</author-notes>
<pub-date pub-type="ppub">
<month>09</month>
<year>2020</year></pub-date>
<pub-date pub-type="epub">
<day>26</day>
<month>06</month>
<year>2020</year></pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>1925</fpage>
<lpage>1934</lpage>
<history>
<date date-type="received">
<day>24</day>
<month>04</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>02</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright: &#x00A9; Peng et al.</copyright-statement>
<copyright-year>2020</copyright-year>
<license license-type="open-access">
<license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivs License</ext-link>, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.</license-p></license>
</permissions>
<abstract>
<p>The present study aimed to investigate the expression levels of C-X-C motif chemokine receptor 4 (CXCR4) and CXC ligand 12 (CXCL12) in patients with rheumatoid arthritis (RA) and the correlation with disease activity. In total, 60 patients with RA were selected as the study group, comprising of 28 patients in active-stage and 32 patients in remission-stage. In addition, 60 patients with osteoarthritis were selected as the control group. Western blotting and ELISA were used to detect the expression of CXCR4 and CXCL12, respectively. The Spearman&#x0027;s correlation test was used to analyze correlations between CXCR4 and CXCL12, and erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), disease activity score 28 (DAS28) scores and rheumatoid factor (RF). The present results suggested that CXCR4 and CXCL12 expression levels in the serum and joint synovial fluid of the study group were significantly higher compared with the control group (P&#x003C;0.05). Moreover, CXCR4 and CXCL12 expression levels in the RA-active group were higher compared with the remission (P&#x003C;0.05) and control groups (P&#x003C;0.01). The Pearson test results suggested that the expression levels of CXCR4 and CXCL12 in the serum and joint synovial fluid of patients with RA had a positive correlation with the ESR, CRP, RF and DAS28 scores (P&#x003C;0.05). CXCL12 and CXCR4 were highly expressed in the serum and joint synovial fluid of patients with RA, and these expression levels were positively correlated with ESR, CRP, RF and DAS28 scores. Therefore, these clinical parameters may be used as indicators to evaluate the disease activity of patients with RA.</p>
</abstract>
<kwd-group>
<kwd>rheumatoid arthritis</kwd>
<kwd>C-X-C motif chemokine receptor 4</kwd>
<kwd>C-X-C motif chemokine ligand 12</kwd>
<kwd>disease activity</kwd>
<kwd>diagnostic indicators</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec sec-type="intro">
<title>Introduction</title>
<p>Rheumatoid arthritis (RA) is a common systemic autoimmune disease (<xref rid="b1-etm-0-0-8950" ref-type="bibr">1</xref>). The primary pathological manifestations of RA are chronic synovium inflammation and pannus formation, which can lead to swelling and deformities in the joints of patients (<xref rid="b2-etm-0-0-8950" ref-type="bibr">2</xref>). These symptoms can later lead to disability, which may cause a loss of work time, which can create a burden on society and the families of patients (<xref rid="b3-etm-0-0-8950" ref-type="bibr">3</xref>). The pathogenesis of RA is complex, involving many types of cells, including macrophages, T and B cells, fibroblasts, chondrocytes and dendritic cells (<xref rid="b4-etm-0-0-8950" ref-type="bibr">4</xref>). Despite study into the role of many genes and mechanisms underlying the development of RA, there is still no clear predisposing factor (<xref rid="b5-etm-0-0-8950 b6-etm-0-0-8950 b7-etm-0-0-8950" ref-type="bibr">5-7</xref>).</p>
<p>Chemokines are small protein cytokines, and their main function is to induce leukocytes aggregation to form inflammatory lesions, via directional migration, for participation in the inflammatory response (<xref rid="b8-etm-0-0-8950" ref-type="bibr">8</xref>). Previous studies have demonstrated that many chemokines are highly expressed in the joint synovial fluid or peripheral blood of patients with RA, which suggests that chemokines may be associated with RA pathogenesis (<xref rid="b9-etm-0-0-8950" ref-type="bibr">9</xref>,<xref rid="b10-etm-0-0-8950" ref-type="bibr">10</xref>).</p>
<p>C-X-C motif chemokine ligand 12 (CXCL12) is mainly produced by stromal cells and is a key factor for the activation and migration of inflammatory cells to synovial tissues (<xref rid="b11-etm-0-0-8950" ref-type="bibr">11</xref>). CXC receptor 4 (CXCR4) is a natural receptor of CXCL12(<xref rid="b12-etm-0-0-8950" ref-type="bibr">12</xref>). The chemokine CXCL12 can participate in the immune response to RA by mediating the migration and activation of T and B cells in immune cells (<xref rid="b13-etm-0-0-8950" ref-type="bibr">13</xref>). CXCL12 can also be secreted and produced by joint synovial cells, while CXCR4 can be expressed on the surface of articular chondrocytes (<xref rid="b14-etm-0-0-8950" ref-type="bibr">14</xref>,<xref rid="b15-etm-0-0-8950" ref-type="bibr">15</xref>). The activation of CXCR4 and CXCL12 can induce the secretion of a variety of inflammatory factors from articular chondrocytes, leading to apoptosis and destruction of chondrocytes (<xref rid="b16-etm-0-0-8950" ref-type="bibr">16</xref>,<xref rid="b17-etm-0-0-8950" ref-type="bibr">17</xref>). Previous studies have demonstrated that CXCR4 and CXCL12 together can serve an important role in lupus erythematosus (<xref rid="b18-etm-0-0-8950 b19-etm-0-0-8950 b20-etm-0-0-8950" ref-type="bibr">18-20</xref>). These aforementioned studies indicated that CXCR4 and CXCL12 are closely associated with autoimmune diseases.</p>
<p>Although previous studies have indicated that the expression of CXCL12 in the joint synovial membranes was significantly higher in the patients with RA compared with healthy controls (<xref rid="b21-etm-0-0-8950" ref-type="bibr">21</xref>), there are relatively few studies on the relationship between CXCR4 and CXCL12, and disease activity in patients with RA. Therefore, the present study investigated the expression levels of CXCR4 and CXCL12 in the serum and joint synovial fluid of patients with RA, and correlation analyses was performed to examine this data with clinical indicators. In addition, the present study investigated the roles of CXCR4 and CXCL12 in the occurrence and development of RA, and the relationship between CXCR4, CXCL12 and disease activity, to identify accurate evaluation indicators for use in patients with RA.</p>
</sec>
<sec sec-type="Materials|methods">
<title>Materials and methods</title>
<sec>
<title/>
<sec>
<title>Patient data</title>
<p>Using a random number table method, 60 patients (male patients, 34; female patients, 26) with RA were recruited and randomly selected as the study group from the Rheumatology and Immunology Department of First People&#x0027;s Hospital of Jingzhou from January 1 to December 31, 2018. The age distribution was 32-60 years old. The average age of all patients was 54.31&#x00B1;5.89 years. Another 60 patients (male patients, 32; female patients, 28) with osteoarthritis, recruited from The First People&#x0027;s Hospital of Jingzhou hospital were selected as the control group.</p>
<p>Patients were selected based on inclusion and exclusion criteria. Patients who met the RA diagnostic criteria revised by The American College of Rheumatology in 1987(<xref rid="b22-etm-0-0-8950" ref-type="bibr">22</xref>) were included in the study group, and patients who met the guidelines on management of osteoarthritis of the hand, hip and knee by the American College of Rheumatology (<xref rid="b23-etm-0-0-8950" ref-type="bibr">23</xref>) were included in the control group. Patients were excluded if they had any joint infection, severe liver or kidney dysfunction, cognitive or communication disorders, other autoimmune diseases or malignant tumors, or those who declined to participle. All patients agreed to participate in the experiment and signed an informed consent agreement. This experiment has been approved by the Hospital Ethics Committee of First People&#x0027;s Hospital of Jingzhou.</p>
</sec>
<sec>
<title>Specimen extraction</title>
<p>A total of 5 ml fasting venous blood was obtained from all patients and centrifuged at 1,500 x g for 10 min at 4&#x02DA;C. The serum was collected following centrifugation (1,500 x g for 10 min at 4&#x02DA;C) and stored at -80&#x02DA;C. A total of 500 &#x00B5;l joint fluid specimens were collected by outpatient joint punctures or knee joint surgery, and stored at -80&#x02DA;C for subsequent analysis. Western blotting (WB) and ELISA were used to detect the expression levels of CXCR4 and CXCL12, respectively, in serum and joint fluid.</p>
</sec>
<sec>
<title>Detection of CXCR4 expression level using WB</title>
<p>200 &#x00B5;l Radioimmunoprecipitation assay buffer (Cell Signaling Technology, Inc.) was added to the serum and joint fluid specimens collected from patients. The cells were lysed and the total protein of each group was collected. BCA assays were used to determine the protein concentration. After collection, the protein was boiled in water for 8 min at 100&#x02DA;C. A total of 20 &#x00B5;g protein was loaded into the 10&#x0025; SDS-PAGE gel and run at 140 V for 2 h. Subsequently, the protein was transferred to a PVDF membrane at 300 mA for 2 h, and PVDF membrane was blocked with 5&#x0025; skimmed milk powder for 2 h at room temperature. The membranes were probed with the primary antibody targeting CXCR4 (1:1,000; Abcam; cat. no. ab227767) incubated overnight at 4&#x02DA;C. The antibody GAPDH (1:500; Wuhan Fine Biotech Co., Ltd.; cat. no. FNab03342) was added and incubated overnight at 4&#x02DA;C, then the membrane was probed with horseradish peroxidase (HRP)-labeled goat anti-rabbit secondary antibodies (1:5,000; Abcam; cat. no. ab97080) at room temperature for 2 h. Subsequently, an enhanced chemiluminescence (ECL) developer (Invitrogen; Thermo Fisher Scientific, Inc.) was used to develop the protein bands. Filter paper was used to absorb excess liquid from the film and protein bands were developed for film-imaged using ECL. The protein bands were scanned and analyzed using Quantity One software (v4.6.6; Bio-Rad Laboratories, Inc.), where the relative expression level of the protein = the gray value of the target protein band/the grey value of the GAPDH protein band.</p>
</sec>
<sec>
<title>Detection of CXCL12 expression in serum and joint fluid of patients using ELISA</title>
<p>The ELISA kit was purchased from Quanzhou Ruixin Biotechnology Co., Ltd. (cat. no. 13236). A total of 50 &#x00B5;l of the diluted standard and samples were added into each reaction well, followed by 50 &#x00B5;l biotin-labeled antibodies (all provided as part of the aforementioned kit). These samples were incubated at 37&#x02DA;C for 1 h and then washed using the wash buffer, 4 times for 5 min each time. Streptomycin-HRP conjugate from the aforementioned kit was added and incubated for 30 min at room temperature. Subsequently, a total of 50 &#x00B5;l substrates provided by the aforementioned kit were added and incubated for 10 min at 37&#x02DA;C. Subsequently, 50 &#x00B5;l terminating solution, provided by the aforementioned kit, was added to each well and the OD values were measured at 450 nm.</p>
</sec>
<sec>
<title>Detection of routine detection indexes in patients with RA</title>
<p>The erythrocyte sedimentation rate (ESR) from the patients with RA was detected using the Westergren&#x0027;s method (<xref rid="b24-etm-0-0-8950" ref-type="bibr">24</xref>) using an automatic erythrocyte sedimentation rate tester (Plyson cat. no. LBY-XC40B). C-reactive protein (CRP) and the rheumatoid factor (RF) were detected using rate scatter nephelometry (<xref rid="b25-etm-0-0-8950" ref-type="bibr">25</xref>) using an IMMAGE rate scattering turbidity analyzer (UniCel DxC800; Beckman Coulter, Inc.).</p>
</sec>
<sec>
<title>Outcome measures</title>
<p>The outcome measures were as follows: i) The levels of CXCR4 and CXCL12 in serum and joint fluid were compared between the study and control groups; ii) patients with RA were divided based on their disease activity score 28 (DAS28) scores (<xref rid="b13-etm-0-0-8950" ref-type="bibr">13</xref>) into the remission group (28 cases; &#x2264;2.6 points) and the active group (32 cases; &#x003E;2.6 points), which were evaluated from four aspects, including the number of tender joints, the number of swollen joints and the erythrocyte sedimentation rate. DAS28 values range from 2.0-10.0(<xref rid="b13-etm-0-0-8950" ref-type="bibr">13</xref>). A DAS28 &#x003C;2.6 is interpreted as &#x0027;remission&#x0027;; and iii) CXCR4 and CXCL12 expression levels in the serum and joint fluid of patients were compared. Correlations were analyzed between CXCR4 and CXCL12 expression levels, and ESR, CRP, DAS28 scores and RF in patients with RA.</p>
</sec>
<sec>
<title>Statistical analysis</title>
<p>SPSS 18.0 statistical software (SPSS Inc.) was used to analyze the experimental data. Data are presented as the mean &#x00B1; standard deviation. A &#x03C7;<sup>2</sup> test was used to analyze categorical data. An independent t-test was used for comparison between two groups. One-way ANOVA with a post-hoc LSD test was used for comparison among three groups. Spearman&#x0027;s correlation was used to analyze the correlation between CXCR4 and CXCL12 expression levels. The figures in this study were drawn using Graph Pad Prism 6 software (GraphPad Software, Inc.). P&#x003C;0.05 was considered to indicate a statistically significant difference.</p>
</sec>
</sec>
</sec>
<sec sec-type="Results">
<title>Results</title>
<sec>
<title/>
<sec>
<title>Patient data</title>
<p>There were no significant differences between sex, age or body mass index in the two groups (<xref rid="tI-etm-0-0-8950" ref-type="table">Table I</xref>).</p>
</sec>
<sec>
<title>CXCR4 and CXCL12 expression levels among the study and control groups</title>
<p>The serum CXCR4 expression levels of the study group were 5.12&#x00B1;1.04 and 3.62&#x00B1;0.54, and the serum CXCL12 expression levels were 8.28&#x00B1;1.23 and 7.31&#x00B1;1.69. The joint fluid CXCR4 expression levels of the control group were 3.05&#x00B1;1.11 and 2.13&#x00B1;0.63, and the joint fluid CXCL12 expression levels were 5.14&#x00B1;1.12 and 4.54&#x00B1;1.25. The present results suggested that CXCR4 and CXCL12 expression levels in the serum and articular fluid of the study group were significantly higher compared with the control group (P&#x003C;0.05; <xref rid="tII-etm-0-0-8950" ref-type="table">Tables II</xref> and <xref rid="tIII-etm-0-0-8950" ref-type="table">III</xref>; <xref rid="f1-etm-0-0-8950" ref-type="fig">Figs. 1</xref> and <xref rid="f2-etm-0-0-8950" ref-type="fig">2</xref>).</p>
</sec>
<sec>
<title>CXCR4 and CXCL12 expression levels among the RA, remission and control groups</title>
<p>The serum CXCR4 expression levels of the RA-active group were 7.85&#x00B1;1.21 and 6.71&#x00B1;0.69, and the serum CXCL12 expression levels were 10.82&#x00B1;1.33 and 9.46&#x00B1;1.59. CXCR4 expression levels of the RA-remission group were 3.33&#x00B1;1.05 and 2.41&#x00B1;0.57, and CXCL12 expression levels were 5.18&#x00B1;1.15 and 4.74&#x00B1;1.39. The joint fluid CXCR4 expression levels of the control group were 3.05&#x00B1;1.11 and 2.13&#x00B1;0.63, and the joint fluid CXCL12 expression levels were 5.14&#x00B1;1.12 and 4.54&#x00B1;1.25. Therefore, the present results suggested that the expression levels of CXCR4 and CXCL12 in the RA-active group were significantly higher compared with the RA-remission (P&#x003C;0.05) and control groups (P&#x003C;0.05; <xref rid="tIV-etm-0-0-8950" ref-type="table">Tables IV</xref> and <xref rid="tV-etm-0-0-8950" ref-type="table">V</xref>; <xref rid="f3-etm-0-0-8950" ref-type="fig">Figs. 3</xref> and <xref rid="f4-etm-0-0-8950" ref-type="fig">4</xref>).</p>
</sec>
<sec>
<title>Correlations between CXCR4 and CXCL12 expression levels and ESR, CRP, RF and DAS28 scores</title>
<p>The expression levels of CXCR4 and CXCL12 had a positive correlation with the ESR, CRP, RF and DAS28 scores (data not shown) of patients with RA (P&#x003C;0.05; <xref rid="tVI-etm-0-0-8950" ref-type="table">Tables VI</xref> and <xref rid="tVII-etm-0-0-8950" ref-type="table">VII</xref>; <xref rid="f5-etm-0-0-8950 f6-etm-0-0-8950 f6-etm-0-0-8950 f8-etm-0-0-8950" ref-type="fig">Figs. 5-8</xref>).</p>
</sec>
<sec>
<title>Correlation between the expression of CXCR4 and CXCL12 with disease activity</title>
<p>Compared with the RA-active group, the expression of CXCR4 and CXCL12 in the serum of the RA remission group was significantly lower. Therefore, the present results suggested that the expression levels of CXCR4 and CXCL12 were positively correlated with the changes in RA disease activity (CXCR4, r=0.858, P&#x003C;0.001; CXCL12, r=0.864, P&#x003C;0.001; <xref rid="f9-etm-0-0-8950" ref-type="fig">Fig. 9</xref>).</p>
</sec>
</sec>
</sec>
<sec sec-type="Discussion">
<title>Discussion</title>
<p>RA is a chronic systemic immune disease and its pathogenesis has yet to be elucidated, but abnormal immunity is considered to contribute to its development (<xref rid="b26-etm-0-0-8950" ref-type="bibr">26</xref>). Previous studies have demonstrated that over the course of RA, inflammatory cells migrate from peripheral blood to synovial tissues and secrete a variety of inflammatory factors, resulting in the destruction of the synovial membrane (<xref rid="b27-etm-0-0-8950" ref-type="bibr">27</xref>,<xref rid="b28-etm-0-0-8950" ref-type="bibr">28</xref>). Chemokines serve an important role in the infiltration and migration of inflammatory cells (<xref rid="b29-etm-0-0-8950" ref-type="bibr">29</xref>). CXCL12 is the only chemokine that binds to the receptor CXCR4(<xref rid="b30-etm-0-0-8950" ref-type="bibr">30</xref>). CXCL12 and CXCR4 promote the migration of monocytes and T lymphocytes, and serve an important role in the process of inflammation (<xref rid="b31-etm-0-0-8950" ref-type="bibr">31</xref>). Previous studies have indicated that the expression levels of CXCL12 in the synovial tissue and joint fluid of patients with RA was increased, and that CXCR4 expression was also significantly increased in T lymphocytes (<xref rid="b32-etm-0-0-8950 b33-etm-0-0-8950 b34-etm-0-0-8950" ref-type="bibr">32-34</xref>).</p>
<p>CXCL12 can promote the secretion of matrix metalloproteins (MMPs) via chondrocytes, including MMP-1 and MMP-13(<xref rid="b35-etm-0-0-8950" ref-type="bibr">35</xref>). CXCR4 receptor antagonists have been used to reduce the expression levels of MMP-1 and MMP-13 in synovial fluid in patients with RA (<xref rid="b36-etm-0-0-8950" ref-type="bibr">36</xref>). In addition, CXCL12 and CXCR4 can further induce injury of the articular cartilage by promoting MMP secretion (<xref rid="b37-etm-0-0-8950" ref-type="bibr">37</xref>). Previous studies have demonstrated that CXCL12 and CXCR4 are closely associated with synovial cell inflammation in patients with RA (<xref rid="b17-etm-0-0-8950" ref-type="bibr">17</xref>,<xref rid="b38-etm-0-0-8950" ref-type="bibr">38</xref>), but to the best of our knowledge, no previous reports have discussed the correlation between CXCL12 and CXCR4, or disease activity in patients with RA.</p>
<p>The present results suggested that the expression levels of CXCR4 and CXCL12 in the RA-active group were significantly higher compared with the RA-remission and control groups (P&#x003C;0.05), but there was no significant difference between the latter two groups. Therefore, the present results indicated that the expression levels of CXCR4 and CXCL12 may be closely associated with RA pathogenesis. The correlations between CXCR4 and CXCL12 expression levels, and ESR, CRP, RF and DAS28 scores in patients with RA were also investigated. The present results suggested that CXCR4 and CXCL12 expression levels were strongly positively correlated with ESR, CRP, RF and DAS28 scores (P&#x003C;0.05). Therefore, these results indicated that CXCR4 and CXCL12 expression levels exhibited an effect on the disease activity of patients with RA and may be used as an index to evaluate this activity.</p>
<p>Previous studies have revealed that when CXCR4 and CXCL12 expression levels were increased, chemotaxis and activating effects were induced in immune cells, which leads to overactivation of immune cells and the subsequent secretion of additional inflammatory factors and their corresponding antibodies (<xref rid="b39-etm-0-0-8950 b40-etm-0-0-8950 b41-etm-0-0-8950" ref-type="bibr">39-41</xref>). This effect may explain the results of the present study, in which the CXCR4 and CXCL12 expression levels of patients with RA were significantly increased. Previous studies have indicated that synovial fibroblasts in patients with RA may produce high levels of CXCL12 compared with patients with osteoarthritis (<xref rid="b21-etm-0-0-8950" ref-type="bibr">21</xref>,<xref rid="b42-etm-0-0-8950" ref-type="bibr">42</xref>). This is primarily due to the hypomethylation of DNA in synovial fibroblasts in patients with RA compared with patients with osteoarthritis, which may affect CXCL12 expression (<xref rid="b43-etm-0-0-8950" ref-type="bibr">43</xref>). The results from these previous studies are in line with the results of the present study. In addition, previous studies have indicated that high expression levels of CXCL12 in patients with RA are associated with a variety of pathogenic events, and that the expression of CXCL12 was positively correlated with the expression of CRP, which is consistent with results from the present study (<xref rid="b44-etm-0-0-8950" ref-type="bibr">44</xref>,<xref rid="b45-etm-0-0-8950" ref-type="bibr">45</xref>). Moreover, other studies have used immunohistochemistry scoring to study synovial tissues of patients with RA and revealed that CXCL12 expression level was significantly correlated with DAS28 scores, and that the expression levels of CXCL12 and CXCR4 were closely associated with disease activity and joint destruction (<xref rid="b46-etm-0-0-8950" ref-type="bibr">46</xref>,<xref rid="b47-etm-0-0-8950" ref-type="bibr">47</xref>). Previous studies indicated that CXCL12/CXCR4 expression were positively correlated with RF expression (<xref rid="b48-etm-0-0-8950 b49-etm-0-0-8950 b50-etm-0-0-8950" ref-type="bibr">48-50</xref>), which was consistent with the results of the present study.</p>
<p>In conclusion, the results of the present study suggested that CXCL12 and CXCR4 are highly expressed in patients with RA, and that these levels are positively correlated with the ESR, CRP, RF and DAS28 scores. Collectively, the results of the current study suggested that these factors may be used as indexes to evaluate disease activity in patients with RA.</p>
<p>However, there are some limitations to the present study. Firstly, the present results indicated that CXCL12 and CXCR4 expression levels were increased in patients with RA, but it is unknown whether the continuous increase of CXCL12 and CXCR4 expression levels were related to disease severity. Correlational analyses were conducted between the expression levels of CXCL12 and CXCR4, and the related indexes of disease activity, but further analysis was not performed. Secondly, a close relationship was revealed between CXCL12 and CXCR4 and inflammation in patients with RA, but the correlation between CXCL12 and CXCR4, and the expression of related inflammatory factors was not analyzed. Inflammatory factors serve an important role in the pathogenesis of RA and are important for the clinical evaluation of the prognosis of patients with RA (<xref rid="b51-etm-0-0-8950" ref-type="bibr">51</xref>). In addition, due to the random array method for sample selection and the limited sample size, there may be a certain deviation between the research group and the control group. The present study recruited patients with osteoarthritis as the control group, rather than healthy individuals, as it is possible to extract bone and joint fluid during the examination of patients with osteoarthritis but not healthy individuals. However, the patients with osteoarthritis did not have rheumatic diseases, thus the selection may result in some bias. Future studies will further increase the sample size and recruit a more suitable selection of individuals as controls.</p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Not applicable.</p>
</ack>
<sec>
<title>Funding</title>
<p>This work was supported by Scientific Research Project of Health Department of Hubei Province (grant no. JX6C-29).</p>
</sec>
<sec>
<title>Availability of data and materials</title>
<p>The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.</p>
</sec>
<sec>
<title>Authors&#x0027; contributions</title>
<p>LP and BW conceived the study and designed the experiments. NZ, JM and LH contributed to the data collection and performed the experiments. YY, ZZ and LW performed the data analysis and interpreted the results. LP and NZ wrote the manuscript. BW contributed to the critical revision of article. All authors read and approved the final manuscript.</p>
</sec>
<sec>
<title>Ethics approval and consent to participate</title>
<p>All patients and their families agreed to participate in the experiment and signed an informed consent agreement. This experiment was approved by the Hospital Ethics Committee of First People&#x0027;s Hospital of Jingzhou.</p>
</sec>
<sec>
<title>Patient consent for publication</title>
<p>Not applicable.</p>
</sec>
<sec>
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="b1-etm-0-0-8950"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lowin</surname><given-names>T</given-names></name><name><surname>Straub</surname><given-names>RH</given-names></name></person-group><article-title>Synovial fibroblasts integrate inflammatory and neuroendocrine stimuli to drive rheumatoid arthritis</article-title><source>Expert Rev Clin Immunol</source><volume>11</volume><fpage>1069</fpage><lpage>1071</lpage><year>2015</year><pub-id pub-id-type="pmid">26163397</pub-id><pub-id pub-id-type="doi">10.1586/1744666X.2015.1066674</pub-id></element-citation></ref>
<ref id="b2-etm-0-0-8950"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>D</given-names></name><name><surname>Nossent</surname><given-names>J</given-names></name><name><surname>Pavlos</surname><given-names>NJ</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name></person-group><article-title>Rheumatoid arthritis: Pathological mechanisms and modern pharmacologic therapies</article-title><source>Bone Res</source><volume>6</volume><issue>15</issue><year>2018</year><pub-id pub-id-type="pmid">29736302</pub-id><pub-id pub-id-type="doi">10.1038/s41413-018-0016-9</pub-id></element-citation></ref>
<ref id="b3-etm-0-0-8950"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lehmann</surname><given-names>J</given-names></name><name><surname>J&#x00FC;ngel</surname><given-names>A</given-names></name><name><surname>Lehmann</surname><given-names>I</given-names></name><name><surname>Busse</surname><given-names>F</given-names></name><name><surname>Biskop</surname><given-names>M</given-names></name><name><surname>Saalbach</surname><given-names>A</given-names></name><name><surname>Emmrich</surname><given-names>F</given-names></name><name><surname>Sack</surname><given-names>U</given-names></name></person-group><article-title>Grafting of fibroblasts isolated from the synovial membrane of rheumatoid arthritis (RA) patients induces chronic arthritis in SCID mice-A novel model for studying the arthritogenic role of RA fibroblasts in vivo</article-title><source>J Autoimmun</source><volume>15</volume><fpage>301</fpage><lpage>313</lpage><year>2000</year><pub-id pub-id-type="pmid">11040071</pub-id><pub-id pub-id-type="doi">10.1006/jaut.2000.0435</pub-id></element-citation></ref>
<ref id="b4-etm-0-0-8950"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leblond</surname><given-names>A</given-names></name><name><surname>Allanore</surname><given-names>Y</given-names></name><name><surname>Avouac</surname><given-names>J</given-names></name></person-group><article-title>Targeting synovial neoangiogenesis in rheumatoid arthritis</article-title><source>Autoimmun Rev</source><volume>16</volume><fpage>594</fpage><lpage>601</lpage><year>2017</year><pub-id pub-id-type="pmid">28414154</pub-id><pub-id pub-id-type="doi">10.1016/j.autrev.2017.04.005</pub-id></element-citation></ref>
<ref id="b5-etm-0-0-8950"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Picerno</surname><given-names>V</given-names></name><name><surname>Ferro</surname><given-names>F</given-names></name><name><surname>Adinolfi</surname><given-names>A</given-names></name><name><surname>Valentini</surname><given-names>E</given-names></name><name><surname>Tani</surname><given-names>C</given-names></name><name><surname>Alunno</surname><given-names>A</given-names></name></person-group><article-title>One year in review: The pathogenesis of rheumatoid arthritis</article-title><source>Clin Exp Rheumatol</source><volume>33</volume><fpage>551</fpage><lpage>558</lpage><year>2015</year><pub-id pub-id-type="pmid">26203933</pub-id></element-citation></ref>
<ref id="b6-etm-0-0-8950"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrii</surname><given-names>IR</given-names></name><name><surname>James</surname><given-names>D</given-names></name></person-group><comment>The three dimensions of somatic evolution: Integrating the role of genetic damage, life history traits and aging in carcinogenesis. Evol Appl: Mar 9, 2020 (Epub ahead of print). doi: 10.1111/eva.12947.</comment></element-citation></ref>
<ref id="b7-etm-0-0-8950"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foretz</surname><given-names>M</given-names></name><name><surname>Guigas</surname><given-names>B</given-names></name><name><surname>Viollet</surname><given-names>B</given-names></name></person-group><article-title>Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus</article-title><source>Nat Rev Endocrinol</source><volume>15</volume><fpage>569</fpage><lpage>589</lpage><year>2019</year><pub-id pub-id-type="pmid">31439934</pub-id><pub-id pub-id-type="doi">10.1038/s41574-019-0242-2</pub-id></element-citation></ref>
<ref id="b8-etm-0-0-8950"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Braunersreuther</surname><given-names>V</given-names></name><name><surname>Viviani</surname><given-names>GL</given-names></name><name><surname>Mach</surname><given-names>F</given-names></name><name><surname>Montecucco</surname><given-names>F</given-names></name></person-group><article-title>Role of cytokines and chemokines in non-alcoholic fatty liver disease</article-title><source>World J Gastroenterol</source><volume>18</volume><fpage>727</fpage><lpage>735</lpage><year>2012</year><pub-id pub-id-type="pmid">22371632</pub-id><pub-id pub-id-type="doi">10.3748/wjg.v18.i8.727</pub-id></element-citation></ref>
<ref id="b9-etm-0-0-8950"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kotrych</surname><given-names>D</given-names></name><name><surname>Dziedziejko</surname><given-names>V</given-names></name><name><surname>Safranow</surname><given-names>K</given-names></name><name><surname>Drozdzik</surname><given-names>M</given-names></name><name><surname>Pawlik</surname><given-names>A</given-names></name></person-group><article-title>CXCL9 and CXCL10 gene polymorphisms in patients with rheumatoid arthritis</article-title><source>Rheumatol Int</source><volume>35</volume><fpage>1319</fpage><lpage>1323</lpage><year>2015</year><pub-id pub-id-type="pmid">25702175</pub-id><pub-id pub-id-type="doi">10.1007/s00296-015-3234-0</pub-id></element-citation></ref>
<ref id="b10-etm-0-0-8950"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Antonelli</surname><given-names>A</given-names></name><name><surname>Rotondi</surname><given-names>M</given-names></name><name><surname>Fallahi</surname><given-names>P</given-names></name><name><surname>Romagnani</surname><given-names>P</given-names></name><name><surname>Ferrari</surname><given-names>SM</given-names></name><name><surname>Barani</surname><given-names>L</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Serio</surname><given-names>M</given-names></name></person-group><article-title>Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves&#x0027; disease, and modulation by methimazole therapy</article-title><source>Clin Endocrinol (Oxf)</source><volume>64</volume><fpage>189</fpage><lpage>195</lpage><year>2006</year><pub-id pub-id-type="pmid">16430719</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2265.2006.02447.x</pub-id></element-citation></ref>
<ref id="b11-etm-0-0-8950"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosengren</surname><given-names>S</given-names></name><name><surname>Kalunian</surname><given-names>KC</given-names></name><name><surname>Kavanaugh</surname><given-names>A</given-names></name><name><surname>Boyle</surname><given-names>DL</given-names></name></person-group><article-title>CXCL13 as a marker for outcome of rheumatoid arthritis: Comment on the article by Meeuwisse et al</article-title><source>Arthritis Rheum</source><volume>63</volume><fpage>3646</fpage><lpage>3647</lpage><year>2011</year><pub-id pub-id-type="pmid">21834069</pub-id><pub-id pub-id-type="doi">10.1002/art.30585</pub-id></element-citation></ref>
<ref id="b12-etm-0-0-8950"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>ZH</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Oupick&#x00FD;</surname><given-names>D</given-names></name></person-group><article-title>Chloroquine-containing HPMA copolymers as polymeric inhibitors of cancer cell migration mediated by the CXCR4/SDF-1 chemokine axis</article-title><source>ACS Macro Lett</source><volume>5</volume><fpage>342</fpage><lpage>345</lpage><year>2016</year><pub-id pub-id-type="pmid">27795873</pub-id><pub-id pub-id-type="doi">10.1021/acsmacrolett.5b00857</pub-id></element-citation></ref>
<ref id="b13-etm-0-0-8950"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanki</surname><given-names>T</given-names></name><name><surname>Takada</surname><given-names>K</given-names></name><name><surname>Komano</surname><given-names>Y</given-names></name><name><surname>Morio</surname><given-names>T</given-names></name><name><surname>Kanegane</surname><given-names>H</given-names></name><name><surname>Nakajima</surname><given-names>A</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name><name><surname>Miyasaka</surname><given-names>N</given-names></name></person-group><article-title>Chemokine receptor expression and functional effects of chemokines on B cells: Implication in the pathogenesis of rheumatoid arthritis</article-title><source>Arthritis Res Ther</source><volume>11</volume><issue>R149</issue><year>2009</year><pub-id pub-id-type="pmid">19804625</pub-id><pub-id pub-id-type="doi">10.1186/ar2823</pub-id></element-citation></ref>
<ref id="b14-etm-0-0-8950"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brown</surname><given-names>MP</given-names></name><name><surname>Dymock</surname><given-names>DC</given-names></name><name><surname>Merritt</surname><given-names>KA</given-names></name><name><surname>Trumble</surname><given-names>TN</given-names></name></person-group><article-title>Stromal cell-derived factor-1 (SDF-1) validation using equine serum, plasma, and synovial fluid</article-title><source>Osteoarthritis Cartilage</source><volume>22</volume><fpage>S71</fpage><lpage>S71</lpage><year>2014</year><pub-id pub-id-type="pmid">25061703</pub-id><pub-id pub-id-type="doi">10.2460/ajvr.75.8.722</pub-id></element-citation></ref>
<ref id="b15-etm-0-0-8950"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanbe</surname><given-names>K</given-names></name><name><surname>Takemura</surname><given-names>T</given-names></name><name><surname>Takeuchi</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name><name><surname>Takagishi</surname><given-names>K</given-names></name><name><surname>Inoue</surname><given-names>K</given-names></name></person-group><article-title>Synovectomy reduces stromal-cell-derived factor-1 (SDF-1) which is involved in the destruction of cartilage in osteoarthritis and rheumatoid arthritis</article-title><source>J Bone Joint Surg Br</source><volume>86</volume><fpage>296</fpage><lpage>300</lpage><year>2004</year><pub-id pub-id-type="pmid">15046450</pub-id><pub-id pub-id-type="doi">10.1302/0301-620x.86b2.14474</pub-id></element-citation></ref>
<ref id="b16-etm-0-0-8950"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>L</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Jia</surname><given-names>D</given-names></name><name><surname>Hu</surname><given-names>X</given-names></name></person-group><article-title>miR-142-5p as a CXCR4-targeted MicroRNA attenuates SDF-1-induced chondrocyte apoptosis and cartilage degradation via inactivating MAPK signaling pathway</article-title><source>Biochem Res Int</source><volume>2020</volume><issue>4508108</issue><year>2020</year><pub-id pub-id-type="pmid">32047668</pub-id><pub-id pub-id-type="doi">10.1155/2020/4508108</pub-id></element-citation></ref>
<ref id="b17-etm-0-0-8950"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janssens</surname><given-names>R</given-names></name><name><surname>Struyf</surname><given-names>S</given-names></name><name><surname>Proost</surname><given-names>P</given-names></name></person-group><article-title>Pathological roles of the homeostatic chemokine CXCL12</article-title><source>Cytokine Growth Factor Rev</source><volume>44</volume><fpage>51</fpage><lpage>68</lpage><year>2018</year><pub-id pub-id-type="pmid">30396776</pub-id><pub-id pub-id-type="doi">10.1016/j.cytogfr.2018.10.004</pub-id></element-citation></ref>
<ref id="b18-etm-0-0-8950"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Guilpain</surname><given-names>P</given-names></name><name><surname>Chong</surname><given-names>BF</given-names></name><name><surname>Chouzenoux</surname><given-names>S</given-names></name><name><surname>Guillevin</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>XJ</given-names></name><name><surname>Lin</surname><given-names>F</given-names></name><name><surname>Fairhurst</surname><given-names>AM</given-names></name><name><surname>Boudreaux</surname><given-names>C</given-names></name><etal/></person-group><article-title>Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus</article-title><source>Arthritis Rheum</source><volume>62</volume><fpage>3436</fpage><lpage>3446</lpage><year>2010</year><pub-id pub-id-type="pmid">20722038</pub-id><pub-id pub-id-type="doi">10.1002/art.27685</pub-id></element-citation></ref>
<ref id="b19-etm-0-0-8950"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>LD</given-names></name><name><surname>Liang</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>XN</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Niu</surname><given-names>JW</given-names></name><name><surname>Zhou</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Zheng</surname><given-names>WJ</given-names></name><name><surname>Fei</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Contribution and underlying mechanisms of CXCR4 overexpression in patients with systemic lupus erythematosus</article-title><source>Cell Mol Immunol</source><volume>14</volume><fpage>842</fpage><lpage>849</lpage><year>2017</year><pub-id pub-id-type="pmid">27665947</pub-id><pub-id pub-id-type="doi">10.1038/cmi.2016.47</pub-id></element-citation></ref>
<ref id="b20-etm-0-0-8950"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimabad</surname><given-names>MN</given-names></name><name><surname>Khoramdelazad</surname><given-names>H</given-names></name><name><surname>Hassanshahi</surname><given-names>G</given-names></name></person-group><article-title>Genetic variation, biological structure, sources, and fundamental parts played by CXCL12 in pathophysiology of type 1 diabetes mellitus</article-title><source>Int J Diabetes Dev Ctries</source><volume>37</volume><fpage>229</fpage><lpage>239</lpage><year>2017</year></element-citation></ref>
<ref id="b21-etm-0-0-8950"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karouzakis</surname><given-names>E</given-names></name><name><surname>Rengel</surname><given-names>Y</given-names></name><name><surname>J&#x00FC;ngel</surname><given-names>A</given-names></name><name><surname>Kolling</surname><given-names>C</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Michel</surname><given-names>BA</given-names></name><name><surname>Tak</surname><given-names>PP</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Neidhart</surname><given-names>M</given-names></name><name><surname>Ospelt</surname><given-names>C</given-names></name></person-group><article-title>DNA methylation regulates the expression of CXCL12 in rheumatoid arthritis synovial fibroblasts</article-title><source>Genes Immun</source><volume>12</volume><fpage>643</fpage><lpage>652</lpage><year>2011</year><pub-id pub-id-type="pmid">21753787</pub-id><pub-id pub-id-type="doi">10.1038/gene.2011.45</pub-id></element-citation></ref>
<ref id="b22-etm-0-0-8950"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medina</surname><given-names>YF</given-names></name><name><surname>Ru&#x00ED;z-Gaviria</surname><given-names>RE</given-names></name><name><surname>Buitrago-Lopez</surname><given-names>A</given-names></name><name><surname>Villota</surname><given-names>C</given-names></name></person-group><article-title>Physical articular examination in the activity of rheumatoid arthritis: a systematic review of the literature : Systematic review of the literature regarding physical examination in rheumatoid arthritis</article-title><source>Clin Rheumatol</source><volume>37</volume><fpage>1457</fpage><lpage>1464</lpage><year>2018</year><pub-id pub-id-type="pmid">29464524</pub-id><pub-id pub-id-type="doi">10.1007/s10067-018-4015-4</pub-id></element-citation></ref>
<ref id="b23-etm-0-0-8950"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van Thillo</surname><given-names>A</given-names></name><name><surname>Vulsteke</surname><given-names>JB</given-names></name><name><surname>Van Assche</surname><given-names>D</given-names></name><name><surname>Verschueren</surname><given-names>P</given-names></name><name><surname>De Langhe</surname><given-names>E</given-names></name></person-group><article-title>Physical therapy in adult inflammatory myopathy patients: A systematic review</article-title><source>Clin Rheumatol</source><volume>38</volume><fpage>2039</fpage><lpage>2051</lpage><year>2019</year><pub-id pub-id-type="pmid">31115788</pub-id><pub-id pub-id-type="doi">10.1007/s10067-019-04571-9</pub-id></element-citation></ref>
<ref id="b24-etm-0-0-8950"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khalid</surname><given-names>S</given-names></name><name><surname>Javad</surname><given-names>Y</given-names></name><name><surname>Amir</surname><given-names>R</given-names></name></person-group><article-title>Study of erythrocyte sedimentation rate and anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis</article-title><source>Pak Armed Forces Med J</source><volume>67</volume><fpage>283</fpage><lpage>286</lpage><year>2017</year></element-citation></ref>
<ref id="b25-etm-0-0-8950"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Varun</surname><given-names>CN</given-names></name><name><surname>Raju</surname><given-names>R</given-names></name><name><surname>Venkataswamy</surname><given-names>MM</given-names></name><name><surname>Ravi</surname><given-names>V</given-names></name><name><surname>Varambally</surname><given-names>S</given-names></name></person-group><article-title>Procalcitonin and C-reactive protein as peripheral inflammatory markers in antipsychotic drug-free schizophrenia patients</article-title><source>Asian J Psychiatr</source><volume>35</volume><fpage>11</fpage><lpage>14</lpage><year>2018</year><pub-id pub-id-type="pmid">29723719</pub-id><pub-id pub-id-type="doi">10.1016/j.ajp.2018.04.029</pub-id></element-citation></ref>
<ref id="b26-etm-0-0-8950"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liao</surname><given-names>KP</given-names></name></person-group><article-title>Cardiovascular disease in patients with rheumatoid arthritis</article-title><source>Trends Cardiovasc Med</source><volume>27</volume><fpage>136</fpage><lpage>140</lpage><year>2017</year><pub-id pub-id-type="pmid">27612551</pub-id><pub-id pub-id-type="doi">10.1016/j.tcm.2016.07.006</pub-id></element-citation></ref>
<ref id="b27-etm-0-0-8950"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Albus</surname><given-names>E</given-names></name><name><surname>Sinningen</surname><given-names>K</given-names></name><name><surname>Winzer</surname><given-names>M</given-names></name><name><surname>Thiele</surname><given-names>S</given-names></name><name><surname>Baschant</surname><given-names>U</given-names></name><name><surname>Hannemann</surname><given-names>A</given-names></name><name><surname>Fantana</surname><given-names>J</given-names></name><name><surname>Tausche</surname><given-names>AK</given-names></name><name><surname>Wallaschofski</surname><given-names>H</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Milk fat globule-epidermal growth factor 8 (MFG-E8) is a novel anti-inflammatory factor in rheumatoid arthritis in mice and humans</article-title><source>J Bone Miner Res</source><volume>31</volume><fpage>596</fpage><lpage>605</lpage><year>2016</year><pub-id pub-id-type="pmid">26391522</pub-id><pub-id pub-id-type="doi">10.1002/jbmr.2721</pub-id></element-citation></ref>
<ref id="b28-etm-0-0-8950"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Harlow</surname><given-names>L</given-names></name><name><surname>Rosas</surname><given-names>IO</given-names></name><name><surname>Gochuico</surname><given-names>BR</given-names></name><name><surname>Mikuls</surname><given-names>TR</given-names></name><name><surname>Dellaripa</surname><given-names>PF</given-names></name><name><surname>Oddis</surname><given-names>CV</given-names></name><name><surname>Ascherman</surname><given-names>DP</given-names></name></person-group><article-title>Identification of citrullinated hsp90 isoforms as novel autoantigens in rheumatoid arthritis-associated interstitial lung disease</article-title><source>Arthritis Rheum</source><volume>65</volume><fpage>869</fpage><lpage>879</lpage><year>2013</year><pub-id pub-id-type="pmid">23400887</pub-id><pub-id pub-id-type="doi">10.1002/art.37881</pub-id></element-citation></ref>
<ref id="b29-etm-0-0-8950"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Crijns</surname><given-names>H</given-names></name><name><surname>Vanheule</surname><given-names>V</given-names></name><name><surname>Proost</surname><given-names>P</given-names></name></person-group><article-title>Targeting chemokine-glycosaminoglycan interactions to inhibit inflammation</article-title><source>Front Immunol</source><volume>11</volume><issue>483</issue><year>2020</year><pub-id pub-id-type="pmid">32296423</pub-id><pub-id pub-id-type="doi">10.3389/fimmu.2020.00483</pub-id></element-citation></ref>
<ref id="b30-etm-0-0-8950"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cutolo</surname><given-names>P</given-names></name><name><surname>Basdevant</surname><given-names>N</given-names></name><name><surname>Bernadat</surname><given-names>G</given-names></name><name><surname>Bachelerie</surname><given-names>F</given-names></name><name><surname>Ha-Duong</surname><given-names>T</given-names></name></person-group><article-title>Interaction of chemokine receptor CXCR4 in monomeric and dimeric state with its endogenous ligand CXCL12: Coarse-grained simulations identify differences</article-title><source>J Biomol Struct Dyn</source><volume>35</volume><fpage>399</fpage><lpage>412</lpage><year>2017</year><pub-id pub-id-type="pmid">26813575</pub-id><pub-id pub-id-type="doi">10.1080/07391102.2016.1145142</pub-id></element-citation></ref>
<ref id="b31-etm-0-0-8950"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><name><surname>Xue</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name></person-group><article-title>CXCL12/CXCR4: A symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks</article-title><source>Oncogene</source><volume>35</volume><fpage>816</fpage><lpage>826</lpage><year>2016</year><pub-id pub-id-type="pmid">25961926</pub-id><pub-id pub-id-type="doi">10.1038/onc.2015.139</pub-id></element-citation></ref>
<ref id="b32-etm-0-0-8950"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>SH</given-names></name><name><surname>Seki</surname><given-names>K</given-names></name><name><surname>Choi</surname><given-names>BI</given-names></name><name><surname>Kimura</surname><given-names>KB</given-names></name><name><surname>Ito</surname><given-names>A</given-names></name><name><surname>Fujikado</surname><given-names>N</given-names></name><name><surname>Saijo</surname><given-names>S</given-names></name><name><surname>Iwakura</surname><given-names>Y</given-names></name></person-group><article-title>CXC chemokine receptor 4 expressed in T cells plays an important role in the development of collagen-induced arthritis</article-title><source>Arthritis Res Ther</source><volume>12</volume><issue>R188</issue><year>2010</year><pub-id pub-id-type="pmid">20939892</pub-id><pub-id pub-id-type="doi">10.1186/ar3158</pub-id></element-citation></ref>
<ref id="b33-etm-0-0-8950"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armas-Gonz&#x00E1;lez</surname><given-names>E</given-names></name><name><surname>Dom&#x00ED;nguez-Luis</surname><given-names>MJ</given-names></name><name><surname>D&#x00ED;az-Mart&#x00ED;n</surname><given-names>A</given-names></name><name><surname>Arce-Franco</surname><given-names>M</given-names></name><name><surname>Castro-Hern&#x00E1;ndez</surname><given-names>J</given-names></name><name><surname>Danelon</surname><given-names>G</given-names></name><name><surname>Hern&#x00E1;ndez-Hern&#x00E1;ndez</surname><given-names>V</given-names></name><name><surname>Bustabad-Reyes</surname><given-names>S</given-names></name><name><surname>Cantabrana</surname><given-names>A</given-names></name><name><surname>Uguccioni</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of CXCL13 and CCL20 in the recruitment of B cells to inflammatory foci in chronic arthritis</article-title><source>Arthritis Res Ther</source><volume>20</volume><issue>114</issue><year>2018</year><pub-id pub-id-type="pmid">29880013</pub-id><pub-id pub-id-type="doi">10.1186/s13075-018-1611-2</pub-id></element-citation></ref>
<ref id="b34-etm-0-0-8950"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L</given-names></name><name><surname>Amendola</surname><given-names>A</given-names></name><name><surname>Wolf</surname><given-names>B</given-names></name><name><surname>Bollier</surname><given-names>M</given-names></name><name><surname>Albright</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Song</surname><given-names>H</given-names></name><name><surname>Pedersen</surname><given-names>D</given-names></name><etal/></person-group><article-title>Association of chemokine expression in anterior cruciate ligament deficient knee with patient characteristics: Implications for post-traumatic osteoarthritis</article-title><source>Knee</source><volume>27</volume><fpage>36</fpage><lpage>44</lpage><year>2020</year><pub-id pub-id-type="pmid">31727431</pub-id><pub-id pub-id-type="doi">10.1016/j.knee.2019.10.014</pub-id></element-citation></ref>
<ref id="b35-etm-0-0-8950"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>F</given-names></name><name><surname>Moore</surname><given-names>DC</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>G</given-names></name><name><surname>Wei</surname><given-names>X</given-names></name><name><surname>Lee</surname><given-names>JK</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name></person-group><article-title>Attenuation of osteoarthritis via blockade of the SDF-1/CXCR4 signaling pathway</article-title><source>Arthritis Res Ther</source><volume>14</volume><issue>R177</issue><year>2012</year><pub-id pub-id-type="pmid">22849584</pub-id><pub-id pub-id-type="doi">10.1186/ar3930</pub-id></element-citation></ref>
<ref id="b36-etm-0-0-8950"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Buck</surname><given-names>M</given-names></name><name><surname>Gouwy</surname><given-names>M</given-names></name><name><surname>Struyf</surname><given-names>S</given-names></name><name><surname>Opdenakker</surname><given-names>G</given-names></name><name><surname>Van Damme</surname><given-names>J</given-names></name></person-group><article-title>The ectoenzyme-side of matrix metalloproteinases (MMPs) makes inflammation by serum amyloid A (SAA) and chemokines go round</article-title><source>Immunol Lett</source><volume>205</volume><fpage>1</fpage><lpage>8</lpage><year>2019</year><pub-id pub-id-type="pmid">29870759</pub-id><pub-id pub-id-type="doi">10.1016/j.imlet.2018.06.001</pub-id></element-citation></ref>
<ref id="b37-etm-0-0-8950"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>C</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Zeng</surname><given-names>C</given-names></name><name><surname>Cui</surname><given-names>ZK</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>R</given-names></name><etal/></person-group><article-title>Activation of mTORC1 in subchondral bone preosteoblasts promotes osteoarthritis by stimulating bone sclerosis and secretion of CXCL12</article-title><source>Bone Res</source><volume>7</volume><issue>5</issue><year>2019</year><pub-id pub-id-type="pmid">30792936</pub-id><pub-id pub-id-type="doi">10.1038/s41413-018-0041-8</pub-id></element-citation></ref>
<ref id="b38-etm-0-0-8950"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kircher</surname><given-names>M</given-names></name><name><surname>Herhaus</surname><given-names>P</given-names></name><name><surname>Schottelius</surname><given-names>M</given-names></name><name><surname>Buck</surname><given-names>AK</given-names></name><name><surname>Werner</surname><given-names>RA</given-names></name><name><surname>Wester</surname><given-names>HJ</given-names></name><name><surname>Keller</surname><given-names>U</given-names></name><name><surname>Lapa</surname><given-names>C</given-names></name></person-group><article-title>CXCR4-directed theranostics in oncology and inflammation</article-title><source>Ann Nucl Med</source><volume>32</volume><fpage>503</fpage><lpage>511</lpage><year>2018</year><pub-id pub-id-type="pmid">30105558</pub-id><pub-id pub-id-type="doi">10.1007/s12149-018-1290-8</pub-id></element-citation></ref>
<ref id="b39-etm-0-0-8950"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ren</surname><given-names>C</given-names></name><name><surname>Duan</surname><given-names>G</given-names></name></person-group><comment>The expression of SDF-1&#x03B1; and CXCR4 in the peripheral blood patients with rheumatoid arthritis. West Chin Med J, 2018.</comment></element-citation></ref>
<ref id="b40-etm-0-0-8950"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leiblein</surname><given-names>M</given-names></name><name><surname>Ponelies</surname><given-names>N</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Marzi</surname><given-names>J</given-names></name><name><surname>Kontradowitz</surname><given-names>K</given-names></name><name><surname>Geiger</surname><given-names>E</given-names></name><name><surname>Marzi</surname><given-names>I</given-names></name><name><surname>Henrich</surname><given-names>D</given-names></name></person-group><article-title>Increased extracellular ubiquitin in surgical wound fluid provides a chemotactic signal for myeloid dendritic cells</article-title><source>Eur J Trauma Emerg Surg</source><volume>46</volume><fpage>153</fpage><lpage>163</lpage><year>2020</year><pub-id pub-id-type="pmid">30159662</pub-id><pub-id pub-id-type="doi">10.1007/s00068-018-1001-0</pub-id></element-citation></ref>
<ref id="b41-etm-0-0-8950"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Milenkovic</surname><given-names>VM</given-names></name><name><surname>Stanton</surname><given-names>EH</given-names></name><name><surname>Nothdurfter</surname><given-names>C</given-names></name><name><surname>Rupprecht</surname><given-names>R</given-names></name><name><surname>Wetzel</surname><given-names>CH</given-names></name></person-group><article-title>The role of chemokines in the pathophysiology of major depressive disorder</article-title><source>Int J Mol Sci</source><volume>20</volume><issue>20</issue><year>2019</year><pub-id pub-id-type="pmid">31075818</pub-id><pub-id pub-id-type="doi">10.3390/ijms20092283</pub-id></element-citation></ref>
<ref id="b42-etm-0-0-8950"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karouzakis</surname><given-names>E</given-names></name><name><surname>Gay</surname><given-names>RE</given-names></name><name><surname>Michel</surname><given-names>BA</given-names></name><name><surname>Gay</surname><given-names>S</given-names></name><name><surname>Neidhart</surname><given-names>M</given-names></name></person-group><article-title>DNA hypomethylation in rheumatoid arthritis synovial fibroblasts</article-title><source>Arthritis Rheum</source><volume>60</volume><fpage>3613</fpage><lpage>3622</lpage><year>2009</year><pub-id pub-id-type="pmid">19950268</pub-id><pub-id pub-id-type="doi">10.1002/art.25018</pub-id></element-citation></ref>
<ref id="b43-etm-0-0-8950"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Doody</surname><given-names>KM</given-names></name><name><surname>Bottini</surname><given-names>N</given-names></name><name><surname>Firestein</surname><given-names>GS</given-names></name></person-group><article-title>Epigenetic alterations in rheumatoid arthritis fibroblast-like synoviocytes</article-title><source>Epigenomics</source><volume>9</volume><fpage>479</fpage><lpage>492</lpage><year>2017</year><pub-id pub-id-type="pmid">28322585</pub-id><pub-id pub-id-type="doi">10.2217/epi-2016-0151</pub-id></element-citation></ref>
<ref id="b44-etm-0-0-8950"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanbe</surname><given-names>K</given-names></name><name><surname>Takagishi</surname><given-names>K</given-names></name><name><surname>Chen</surname><given-names>Q</given-names></name></person-group><article-title>Stimulation of matrix metalloprotease 3 release from human chondrocytes by the interaction of stromal cell-derived factor 1 and CXC chemokine receptor 4</article-title><source>Arthritis Rheum</source><volume>46</volume><fpage>130</fpage><lpage>137</lpage><year>2002</year><pub-id pub-id-type="pmid">11817585</pub-id><pub-id pub-id-type="doi">10.1002/1529-0131(200201)46:1&#x003C;130::aid-art10020&#x003E;3.0.co;2-d</pub-id></element-citation></ref>
<ref id="b45-etm-0-0-8950"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nanki</surname><given-names>T</given-names></name><name><surname>Hayashida</surname><given-names>K</given-names></name><name><surname>El-Gabalawy</surname><given-names>HS</given-names></name><name><surname>Suson</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>K</given-names></name><name><surname>Girschick</surname><given-names>HJ</given-names></name><name><surname>Yavuz</surname><given-names>S</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group><article-title>Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4<sup>+</sup> T cell accumulation in rheumatoid arthritis synovium</article-title><source>J Immunol</source><volume>165</volume><fpage>6590</fpage><lpage>6598</lpage><year>2000</year><pub-id pub-id-type="pmid">11086103</pub-id><pub-id pub-id-type="doi">10.4049/jimmunol.165.11.6590</pub-id></element-citation></ref>
<ref id="b46-etm-0-0-8950"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kanbe</surname><given-names>K</given-names></name><name><surname>Chiba</surname><given-names>J</given-names></name><name><surname>Inoue</surname><given-names>Y</given-names></name><name><surname>Taguchi</surname><given-names>M</given-names></name><name><surname>Yabuki</surname><given-names>A</given-names></name></person-group><article-title>SDF-1 and CXCR4 in synovium are associated with disease activity and bone and joint destruction in patients with rheumatoid arthritis treated with golimumab</article-title><source>Mod Rheumatol</source><volume>26</volume><fpage>46</fpage><lpage>50</lpage><year>2016</year><pub-id pub-id-type="pmid">25995033</pub-id><pub-id pub-id-type="doi">10.3109/14397595.2015.1054088</pub-id></element-citation></ref>
<ref id="b47-etm-0-0-8950"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Diamond</surname><given-names>P</given-names></name><name><surname>Labrinidis</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>SK</given-names></name><name><surname>Farrugia</surname><given-names>AN</given-names></name><name><surname>Gronthos</surname><given-names>S</given-names></name><name><surname>To</surname><given-names>LB</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>O&#x0027;Loughlin</surname><given-names>PD</given-names></name><name><surname>Evdokiou</surname><given-names>A</given-names></name><name><surname>Zannettino</surname><given-names>AC</given-names></name></person-group><article-title>Targeted disruption of the CXCL12/CXCR4 axis inhibits osteolysis in a murine model of myeloma-associated bone loss</article-title><source>J Bone Miner Res</source><volume>24</volume><fpage>1150</fpage><lpage>1161</lpage><year>2009</year><pub-id pub-id-type="pmid">19335218</pub-id><pub-id pub-id-type="doi">10.1359/jbmr.090210</pub-id></element-citation></ref>
<ref id="b48-etm-0-0-8950"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kamezaki</surname><given-names>K</given-names></name><name><surname>Kikushige</surname><given-names>Y</given-names></name><name><surname>Numata</surname><given-names>A</given-names></name><name><surname>Miyamoto</surname><given-names>T</given-names></name><name><surname>Takase</surname><given-names>K</given-names></name><name><surname>Henzan</surname><given-names>H</given-names></name><name><surname>Aoki</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>K</given-names></name><name><surname>Nonami</surname><given-names>A</given-names></name><name><surname>Kamimura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Rituximab does not compromise the mobilization and engraftment of autologous peripheral blood stem cells in diffuse-large B-cell lymphoma</article-title><source>Bone Marrow Transplant</source><volume>39</volume><fpage>523</fpage><lpage>527</lpage><year>2007</year><pub-id pub-id-type="pmid">17369863</pub-id><pub-id pub-id-type="doi">10.1038/sj.bmt.1705649</pub-id></element-citation></ref>
<ref id="b49-etm-0-0-8950"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>JMJD3 promotes the epithelial-mesenchymal transition and migration of glioma cells via the CXCL12/CXCR4 axis</article-title><source>Oncol Lett</source><volume>18</volume><fpage>5930</fpage><lpage>5940</lpage><year>2019</year><pub-id pub-id-type="pmid">31788067</pub-id><pub-id pub-id-type="doi">10.3892/ol.2019.10972</pub-id></element-citation></ref>
<ref id="b50-etm-0-0-8950"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>XQ</given-names></name><name><surname>Zhang</surname><given-names>ZL</given-names></name><name><surname>Tan</surname><given-names>WF</given-names></name><name><surname>Sun</surname><given-names>XJ</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name></person-group><article-title>Down-regulation of CXCL12/CXCR4 expression alleviates ischemia-reperfusion-induced inflammatory pain via inhibiting glial TLR4 activation in the spinal cord</article-title><source>PLoS One</source><volume>11</volume><issue>e0163807</issue><year>2016</year><pub-id pub-id-type="pmid">27760212</pub-id><pub-id pub-id-type="doi">10.1371/journal.pone.0163807</pub-id></element-citation></ref>
<ref id="b51-etm-0-0-8950"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McInnes</surname><given-names>IB</given-names></name><name><surname>Schett</surname><given-names>G</given-names></name></person-group><article-title>Pathogenetic insights from the treatment of rheumatoid arthritis</article-title><source>Lancet</source><volume>389</volume><fpage>2328</fpage><lpage>2337</lpage><year>2017</year><pub-id pub-id-type="pmid">28612747</pub-id><pub-id pub-id-type="doi">10.1016/S0140-6736(17)31472-1</pub-id></element-citation></ref>
</ref-list>
</back>
<floats-group>
<fig id="f1-etm-0-0-8950" position="float">
<label>Figure 1</label>
<caption><p>Western blotting results of CXCR4 expression levels in the study and control groups. Protein expression levels of CXCR4 in cells isolated from the serum of the study group were compared with the control group. CXCR4, C-X-C motif chemokine receptor 4.</p></caption>
<graphic xlink:href="etm-20-03-1925-g00.tif" />
</fig>
<fig id="f2-etm-0-0-8950" position="float">
<label>Figure 2</label>
<caption><p>Western blotting results of CXCR4 expression levels in the study and control groups. Protein expression levels of CXCR4 in the cells isolated from the joint fluid of the study group compared with the control group. CXCR4, C-X-C motif chemokine receptor 4.</p></caption>
<graphic xlink:href="etm-20-03-1925-g01.tif" />
</fig>
<fig id="f3-etm-0-0-8950" position="float">
<label>Figure 3</label>
<caption><p>CXCR4 expression levels in the serum and joint fluid of the three patient groups. The expression level of CXCR4 in the RA-active group was higher compared with both the remission and control groups. There was no significant difference in the expression level of CXCR4 between the RA-remission and control groups. <sup>&#x002A;</sup>P&#x003C;0.05. CXCR4, C-X-C motif chemokine receptor 4; RA, rheumatoid arthritis.</p></caption>
<graphic xlink:href="etm-20-03-1925-g02.tif" />
</fig>
<fig id="f4-etm-0-0-8950" position="float">
<label>Figure 4</label>
<caption><p>CXCL12 expression levels in the serum and joint fluid of the three patient groups. The expression level of CXCL12 in the RA-active group was higher compared with both the remission and control groups. There was no significant difference in the expression level of CXCL12 between the RA-remission and control groups. <sup>&#x002A;</sup>P&#x003C;0.05. CXCL12, C-X-C motif chemokine ligand 12; RA, rheumatoid arthritis.</p></caption>
<graphic xlink:href="etm-20-03-1925-g03.tif" />
</fig>
<fig id="f5-etm-0-0-8950" position="float">
<label>Figure 5</label>
<caption><p>Correlations between serum CXCR4 expression and the ESR, CRP, RF and DAS28 scores of patients with RA. CXCR4 expression in the serum of patients with RA had a strong positive correlation with (A) ESR, (B) CRP, (C) RF and (D) DAS28 scores. CXCR4, C-X-C motif chemokine receptor 4; RA, rheumatoid arthritis; ESR, sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; DAS28, disease activity score.</p></caption>
<graphic xlink:href="etm-20-03-1925-g04.tif" />
</fig>
<fig id="f6-etm-0-0-8950" position="float">
<label>Figure 6</label>
<caption><p>Correlations between joint fluid CXCR4 expression and the ESR, CRP, RF and DAS28 scores of patients with RA. CXCR4 expression in the joint fluid of patients with RA was had a strong positive correlation with (A) ESR, (B) CRP, (C) RF and (D) DAS28 scores. CXCR4, C-X-C motif chemokine receptor 4; RA, rheumatoid arthritis; ESR, sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; DAS28, disease activity score.</p></caption>
<graphic xlink:href="etm-20-03-1925-g05.tif" />
</fig>
<fig id="f7-etm-0-0-8950" position="float">
<label>Figure 7</label>
<caption><p>Correlations between serum CXCL12 expression and the ESR, CRP, RF, and DAS28 scores of patients with RA. CXCL12 expression in the serum of patients with RA was had a strong positive correlation with (A) ESR, (B) CRP, (C) RF and (D) DAS28 scores. CXCL12, C-X-C motif chemokine ligand 12; RA, rheumatoid arthritis; ESR, sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; DAS28, disease activity score.</p></caption>
<graphic xlink:href="etm-20-03-1925-g06.tif" />
</fig>
<fig id="f8-etm-0-0-8950" position="float">
<label>Figure 8</label>
<caption><p>Correlations between joint fluid CXCL12 expression and the ESR, CRP, RF and DAS28 scores of patients with RA. CXCL12 expression in the joint fluid of patients with RA was had a strong positive correlation with (A) ESR, (B) CRP, (C) RF and (D) DAS28 scores. CXCL12, C-X-C motif chemokine ligand 12; RA, rheumatoid arthritis; ESR, sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; DAS28, disease activity score.</p></caption>
<graphic xlink:href="etm-20-03-1925-g07.tif" />
</fig>
<fig id="f9-etm-0-0-8950" position="float">
<label>Figure 9</label>
<caption><p>Correlations between the expression of CXCR4 and CXCL12 with the patient disease activity. (A) CXCR4 expression was positively correlated with the changes in RA; (B) CXCL12 expression was positively correlated with the changes in RA. CXCL12, C-X-C motif chemokine ligand 12; CXCR4; C-X-C motif chemokine receptor 4; RA, rheumatoid arthritis. <sup>&#x002A;</sup>P&#x003C;0.05 vs. control group.</p></caption>
<graphic xlink:href="etm-20-03-1925-g08.tif" />
</fig>
<table-wrap id="tI-etm-0-0-8950" position="float">
<label>Table I</label>
<caption><p>Patient characteristics.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Characteristic</th>
<th align="center" valign="middle">Study group N=60 (&#x0025;)</th>
<th align="center" valign="middle">Control group N=60 (&#x0025;)</th>
<th align="center" valign="middle">&#x03C7;<sup>2</sup>/t</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Sex</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.090</td>
<td align="center" valign="middle">0.764</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Male</td>
<td align="center" valign="middle">34 (56.67)</td>
<td align="center" valign="middle">32 (53.33)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Female</td>
<td align="center" valign="middle">26 (43.33)</td>
<td align="center" valign="middle">28 (46.67)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Age</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.022</td>
<td align="center" valign="middle">0.882</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2265;54</td>
<td align="center" valign="middle">31 (51.67)</td>
<td align="center" valign="middle">30 (50.00)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x003C;54</td>
<td align="center" valign="middle">29 (48.33)</td>
<td align="center" valign="middle">30 (50.00)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">BMI, kg/m<sup>2</sup></td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.023</td>
<td align="center" valign="middle">0.881</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2264;22</td>
<td align="center" valign="middle">27 (45.00)</td>
<td align="center" valign="middle">26 (43.33)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x003E;22</td>
<td align="center" valign="middle">33 (55.00)</td>
<td align="center" valign="middle">34 (56.67)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Smoking</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">1.808</td>
<td align="center" valign="middle">0.179</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;No</td>
<td align="center" valign="middle">39 (65.00)</td>
<td align="center" valign="middle">38 (63.33)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Yes</td>
<td align="center" valign="middle">21 (35.00)</td>
<td align="center" valign="middle">22 (36.67)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Drinking volume, ml</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">&#x00A0;</td>
<td align="center" valign="middle">0.023</td>
<td align="center" valign="middle">0.879</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x003C;70</td>
<td align="center" valign="middle">37 (61.67)</td>
<td align="center" valign="middle">36 (60.00)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x2265;70</td>
<td align="center" valign="middle">23 (38.33)</td>
<td align="center" valign="middle">14 (40.00)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">Coagulation function</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;APTT, sec</td>
<td align="center" valign="middle">28.23&#x00B1;1.35</td>
<td align="center" valign="middle">28.19&#x00B1;1.41</td>
<td align="center" valign="middle">0.131</td>
<td align="center" valign="middle">0.896</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;PT, sec</td>
<td align="center" valign="middle">11.31&#x00B1;1.15</td>
<td align="center" valign="middle">11.29&#x00B1;1.14</td>
<td align="center" valign="middle">0.078</td>
<td align="center" valign="middle">0.938</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;FIB, g/l</td>
<td align="center" valign="middle">3.16&#x00B1;0.21</td>
<td align="center" valign="middle">3.19&#x00B1;0.19</td>
<td align="center" valign="middle">0.659</td>
<td align="center" valign="middle">0.512</td>
</tr>
<tr>
<td align="left" valign="middle">Renal function index (&#x00B5;mol/l)</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
<td align="left" valign="middle">&#x00A0;</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Creatinine</td>
<td align="center" valign="middle">57.63&#x00B1;4.45</td>
<td align="center" valign="middle">58.01&#x00B1;4.52</td>
<td align="center" valign="middle">0.280</td>
<td align="center" valign="middle">0.705</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Urea</td>
<td align="center" valign="middle">5.29&#x00B1;0.45</td>
<td align="center" valign="middle">5.31&#x00B1;0.57</td>
<td align="center" valign="middle">0.182</td>
<td align="center" valign="middle">0.856</td>
</tr>
<tr>
<td align="left" valign="middle">&#x00A0;&#x00A0;&#x00A0;&#x00A0;&#x00A0;Uric acid</td>
<td align="center" valign="middle">291.34&#x00B1;11.35</td>
<td align="center" valign="middle">293.14&#x00B1;11.45</td>
<td align="center" valign="middle">0.707</td>
<td align="center" valign="middle">0.481</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>APTT, activated partial thromboplastin time; BMI, body mass index; FIB, fibrinogen; PT, prothrombin time.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tII-etm-0-0-8950" position="float">
<label>Table II</label>
<caption><p>CXCR4 expression levels in the serum and joint fluid of the study and control groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Factor</th>
<th align="center" valign="middle">Study group N=60</th>
<th align="center" valign="middle">Control group N=60</th>
<th align="center" valign="middle">t</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Serum</td>
<td align="center" valign="middle">3.12&#x00B1;1.04</td>
<td align="center" valign="middle">3.05&#x00B1;1.11</td>
<td align="center" valign="middle">8.704</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="middle">Joint fluid</td>
<td align="center" valign="middle">3.62&#x00B1;0.54</td>
<td align="center" valign="middle">2.13&#x00B1;0.63</td>
<td align="center" valign="middle">11.67</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>CXCR4, C-X-C motif chemokine receptor 4.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIII-etm-0-0-8950" position="float">
<label>Table III</label>
<caption><p>CXCL12 expression levels in the serum and joint fluid of the study and control groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Factor</th>
<th align="center" valign="middle">Study group N=60</th>
<th align="center" valign="middle">Control group N=60</th>
<th align="center" valign="middle">t</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Serum</td>
<td align="center" valign="middle">8.28&#x00B1;1.23</td>
<td align="center" valign="middle">5.14&#x00B1;1.12</td>
<td align="center" valign="middle">11.75</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="middle">Joint fluid</td>
<td align="center" valign="middle">7.31&#x00B1;1.69</td>
<td align="center" valign="middle">4.54&#x00B1;1.25</td>
<td align="center" valign="middle">7.947</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>CXCL12, C-X-C motif chemokine ligand 12.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tIV-etm-0-0-8950" position="float">
<label>Table IV</label>
<caption><p>CXCR4 expression levels in the serum and joint fluid of the active, remission, and control groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Factor</th>
<th align="center" valign="middle">Active group N=32</th>
<th align="center" valign="middle">Remission group N=28</th>
<th align="center" valign="middle">Control group N=60</th>
<th align="center" valign="middle">F</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Serum</td>
<td align="center" valign="middle">7.85&#x00B1;1.21</td>
<td align="center" valign="middle">3.33&#x00B1;1.05<sup><xref rid="tfn1-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">3.05&#x00B1;1.1<sup><xref rid="tfn1-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">156.7</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="middle">Joint fluid</td>
<td align="center" valign="middle">6.71&#x00B1;0.69</td>
<td align="center" valign="middle">2.41&#x00B1;0.57<sup><xref rid="tfn1-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">2.13&#x00B1;0.63<sup><xref rid="tfn1-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">507.2</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn1-etm-0-0-8950"><p><sup>a</sup>P&#x003C;0.05 vs. active group. CXCR4, C-X-C motif chemokine receptor 4. F, F-test value.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tV-etm-0-0-8950" position="float">
<label>Table V</label>
<caption><p>CXCL12 expression levels in the serum and joint fluid of the active, remission and control groups.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">Factor</th>
<th align="center" valign="middle">Active group N=32</th>
<th align="center" valign="middle">Remission group N=28</th>
<th align="center" valign="middle">Control group N=60</th>
<th align="center" valign="middle">F</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">Serum</td>
<td align="center" valign="middle">10.82&#x00B1;1.33</td>
<td align="center" valign="middle">5.18&#x00B1;1.15<sup><xref rid="tfn2-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">5.14&#x00B1;1.12<sup><xref rid="tfn2-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">226.5</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
<tr>
<td align="left" valign="middle">Joint fluid</td>
<td align="center" valign="middle">9.46&#x00B1;1.59</td>
<td align="center" valign="middle">4.74&#x00B1;1.39<sup><xref rid="tfn2-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">4.54&#x00B1;1.25<sup><xref rid="tfn2-etm-0-0-8950" ref-type="table-fn">a</xref></sup></td>
<td align="center" valign="middle">118.8</td>
<td align="center" valign="middle">&#x003C;0.001</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="tfn2-etm-0-0-8950"><p><sup>a</sup>P&#x003C;0.05 vs. active group. CXCL12, C-X-C motif chemokine ligand 12. F, F-test value.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tVI-etm-0-0-8950" position="float">
<label>Table VI</label>
<caption><p>Correlation between CXCR4 and CXCL12 expression in serum from the patients with RA and ESR, CRP, RF and DAS28 scores.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">&#x00A0;</th>
<th align="center" valign="middle" colspan="2">CXCR4</th>
<th align="center" valign="middle" colspan="2">CXCL12</th>
</tr>
<tr>
<th align="left" valign="middle">Parameter</th>
<th align="center" valign="middle">r</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">r</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">ESR</td>
<td align="center" valign="middle">0.766</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.798</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">CRP</td>
<td align="center" valign="middle">0.836</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.879</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">RF</td>
<td align="center" valign="middle">0.76</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.781</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">DAS28</td>
<td align="center" valign="middle">0.751</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.799</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>CXCR4, C-X-C motif chemokine receptor 4; CXCL12; C-X-C motif chemokine ligand; RA, rheumatoid arthritis; ESR, sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; DAS28, disease activity score.</p></fn>
</table-wrap-foot>
</table-wrap>
<table-wrap id="tVII-etm-0-0-8950" position="float">
<label>Table VII</label>
<caption><p>Correlation between CXCR4 and CXCL12 expression in joint fluid from the patients with RA and ESR, CRP, RF and DAS28 scores.</p></caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" valign="middle">&#x00A0;</th>
<th align="center" valign="middle" colspan="2">CXCR4</th>
<th align="center" valign="middle" colspan="2">CXCL12</th>
</tr>
<tr>
<th align="left" valign="middle">Score</th>
<th align="center" valign="middle">r</th>
<th align="center" valign="middle">P-value</th>
<th align="center" valign="middle">r</th>
<th align="center" valign="middle">P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" valign="middle">ESR</td>
<td align="center" valign="middle">0.703</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.743</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">CRP</td>
<td align="center" valign="middle">0.85</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.858</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">RF</td>
<td align="center" valign="middle">0.788</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.727</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
<tr>
<td align="left" valign="middle">DAS28</td>
<td align="center" valign="middle">0.731</td>
<td align="center" valign="middle">&#x003C;0.05</td>
<td align="center" valign="middle">0.809</td>
<td align="center" valign="middle">&#x003C;0.05</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn><p>CXCR4, C-X-C motif chemokine receptor 4; CXCL12; C-X-C motif chemokine ligand; RA, rheumatoid arthritis; ESR, sedimentation rate; CRP, C-reactive protein; RF, rheumatoid factor; DAS28, disease activity score.</p></fn>
</table-wrap-foot>
</table-wrap>
</floats-group>
</article>
